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Abstract
Type 1 diabetes (T1D) is an autoimmune disease resulting from the complex interaction between multiple susceptibility
genes, environmental factors and the immune system. Over 40 T1D susceptibility regions have been suggested by recent
genome-wide association studies; however, the specific genes and their role in the disease remain elusive. The objective of
this study is to identify the susceptibility gene(s) in the 12q13 region and investigate the functional link to the disease
pathogenesis. A total of 19 SNPs in the 12q13 region were analyzed by the TaqMan assay for 1,434 T1D patients and 1,865
controls. Thirteen of the SNPs are associated with T1D (best p=4610
211), thus providing confirmatory evidence for at least
one susceptibility gene in this region. To identify candidate genes, expression of six genes in the region was analyzed by
real-time RT-PCR for PBMCs from 192 T1D patients and 192 controls. SNP genotypes in the 12q13 region are the main
factors that determine ERBB3 mRNA levels in PBMCs. The protective genotypes for T1D are associated with higher ERBB3
mRNA level (p,10
210). Furthermore, ERBB3 protein is expressed on the surface of CD11c
+ cells (dendritic cells and
monocytes) in peripheral blood after stimulation with LPS, polyI:C or CpG. Subjects with protective genotypes have
significantly higher percentages of ERBB3
+ monocytes and dendritic cells (p=1.1610
29); and the percentages of ERBB3
+
cells positively correlate with the ability of APC to stimulate T cell proliferation (R
2=0.90, p,0.0001). Our results indicate
that ERBB3 plays a critical role in determining APC function and potentially T1D pathogenesis.
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Introduction
With the advances in genome wide association studies (GWAS),
mapping susceptibility genes involved in complex diseases has
become a routine and powerful approach in elucidating the
mechanisms underlying human diseases. The GWAS approach
has been applied to an ever increasing number of diseases
including type 1 diabetes (T1D) and type 2 diabetes among others
[1–9]. However, an intrinsic problem with GWAS is the expected
high false positive rate due to the large number of markers
analyzed [10]. Therefore, putative associations identified by
GWAS must be confirmed in multiple large cohorts. Further,
identification of specific genes involved in the diseases remains a
formidable challenge even after the genomic regions have been
identified by GWAS. The challenges in the next phase of the
genetic studies of complex diseases will most likely be overcome by
combinatorial approaches based on genetic association and
functional characterization of candidate genes located within the
intervals identified by GWAS.
Several studies have reported significant associations with
several SNPs in the 12q13 region [3,7,9,11,12]. These results
suggested that at least one T1D susceptibility gene is located in the
vicinity of these SNPs; however, the specific disease gene(s) have
yet to be identified. In an effort to elucidate the specific disease
genes in this region, we analyzed a large set of cases and controls
from the Georgia population and defined the association interval
to a genomic region of approximately 150kb. By analyzing the
expression of six candidate genes in peripheral blood mononuclear
cells (PBMCs) from a large batch of T1D patients and controls, the
v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)
(ERBB3) gene was identified as a top candidate gene. The
expression-genotype association was further confirmed by analyz-
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11789ing surface protein expression. Functional studies further demon-
strate that ERBB3 on CD11c
+ cells is critical to the function of
antigen presenting cells (APC).
Results
Multiple SNPs in the 12q13 region are significantly
associated with T1D
We genotyped 19 SNPs in the 12q13 region in 1,434
Caucasian cases and 1,865 matched controls collected in
Georgia. Association between the individual SNPs and T1D
was assessed using different methods as described in the Method
section and presented in Table 1. Thirteen SNPs showed highly
significant evidence for association. Five of the six SNPs without
evidence for an association are located at the two flanking sides of
the association interval and mark the approximate boundaries of
the association interval (Figure 1). The SNP with the best
evidence for an association (rs772921, #8) had a p-value of
4610
211 and OR=1.43 as estimated using an additive logistic
regression model. Nine SNPs had p-values of ,10
25 (Table 1).
These results provide strong evidence for association between the
12q13 region and T1D in the Caucasian population in Georgia.
For all SNPs, the minor allele is associated with increased risk for
T1D, while the major allele is associated with lower risk. All
associated SNPs are contained in a genomic region of
approximately 150kb marked by SNPs rs773107 (#4) and
rs4759228 (#16) (Figure 1).
We next tested whether the associations with the 12q13 SNPs
were dependent on other covariates such as gender of the
subjects, age of onset of diabetes or HLA-DQB1 genotypes
using logistic regression. The 12q13 SNPs are significantly
associated with T1D in both early and late onset T1D data sets
with similar OR estimates (Table S1). No significant interaction
was observed between SNPs and HLA genotypes (Table S2) or
sex (Table S3).
Suggestive evidence for multiple disease genes
Linkage disequilibrium (LD) estimated using the entire data set
suggested LD between all SNP pairs from SNP #4t o#16
(Figure 1). However, three LD sub-blocks were suggested by the
HaploView 4.1 program (Figure 1). The LD sub-block 1a includes
three SNPs (#4, 5 and 6) within/near the RAB5B gene (R
2=0.94–
0.96). The LD sub-block 1b contains three SNPs (#8, 9 and 10)
within/near SUOX/IKZF4 (R
2=0.90–0.97), while LD sub-block 2
contains three SNPs within/near ERBB3 (#14, 15 and 16) that
display weak LD (R
2=0.42–0.55). Interestingly, these three LD
sub-blocks coincide with the three association peaks as suggested
by the plots of p-values and OR (Figure 1). Based on the LD sub-
blocks, we examined associations between T1D and haplotypes
within each LD block. Consistent with the strong LD in sub-block
1a (21.1kb) and 1b (13.4kb), only two major haplotypes are found
in both T1D and control subjects and the haplotypes confer
significantly different risk for T1D (Table 2). Significant
associations were also observed between T1D and the two major
haplotypes in sub-block 2 (Table 2) despite the weaker LD
between the SNPs.
Given the LD pattern, the association observed throughout the
region could be due to multiple genes. We used logistic regression
analyses that included multiple SNPs to determine whether
multiple SNPs have independent associations within the region.
A stepwise logistic regression analysis based on the chi-squared
statistic selected four SNPs (Figure 1 & Table S4): one near SUOX
(rs772921), one within SILV (rs1052165), one within RPL41
(rs4759228), and one 59 to ERBB3 (rs1117139). A stepwise SNP
Table 1. Association between T1D and individual SNP genotypes in the 12q13 region.
Logistic regression additive model
SNP # SNP Name Gene Celera Position Minor allele Case freq Cont freq p-value OR LCL UCL
1 rs3138144 RDH5 55767239 G 0.47 0.45 0.18 1.1 1.0 1.2
2 rs772704 WIBG 55968423 C 0.17 0.19 0.04 0.9 0.8 1.0
3 rs1052165 SILV 56004000 T 0.28 0.23 5610
24 1.2 1.1 1.4
4 rs773107 RAB5B 56022190 G 0.38 0.31 4610
29 1.4 1.2 1.5
5 rs705698 RAB5B 56037371 C 0.38 0.32 4610
27 1.3 1.2 1.5
6 rs705702 SUOX 56043320 C 0.37 0.31 3610
26 1.3 1.2 1.4
7 rs10876864 39SUOX 56053768 G 0.47 0.42 2610
25 1.2 1.1 1.4
8 rs772921 59IKZF4 56056261 T 0.38 0.32 4610
211 1.4 1.3 1.6
9 rs1701704 59IKZF4 56065172 C 0.39 0.32 3610
29 1.4 1.2 1.5
10 rs2456973 IKZF4 56069619 G 0.38 0.32 6610
27 1.3 1.2 1.5
11 rs1131017 RPS26 56088616 C 0.46 0.41 1610
24 1.2 1.1 1.3
12 rs12580100 59ERBB3 56091897 G 0.13 0.12 0.43 1.1 0.9 1.2
13 rs11171739 59ERBB3 56122295 C 0.42 0.38 4610
24 1.2 1.1 1.3
14 rs2292239 ERBB3 56133849 A 0.38 0.32 4610
26 1.3 1.2 1.4
15 rs2292238 ERBB3 56146009 G 0.46 0.39 6610
28 1.3 1.2 1.5
16 rs4759228 59RPL41 56160558 G 0.34 0.27 3610
29 1.4 1.3 1.6
17 rs12810816 MYL6 56205104 G 0.10 0.11 0.27 0.9 0.8 1.1
18 rs7311008 SMARCC2 56217536 T 0.09 0.10 0.31 1.1 0.9 1.3
19 rs2291738 TIMELESS 56468655 G 0.49 0.47 0.43 1.0 0.9 1.2
OR: odds ratio, LCL: lower confidence limit, UCL: upper confidence limit.
doi:10.1371/journal.pone.0011789.t001
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PLoS ONE | www.plosone.org 2 July 2010 | Volume 5 | Issue 7 | e11789Figure 1. T1D is significantly associated with SNPs in the 12q13 region. Shown are LD map (top), odds ratios and 95% confidence interval
(OR and CI), and 2Log 10 p-values. The 150-kb region defined by SNP #4 and #16 showed some LD as indicated by the R
2 values between pairs of
SNPs. Three LD sub-blocks were identified by the HaploView 4.1 program, although there is strong LD throughout the region. The numbers below
the SNPs indicate the relative importance of SNPs based on analyses aimed at determining independent effects. For the chi-square and BIC based
analyses, the numbers indicate the order in which the SNP was entered in stepwise analyses. For the Lasso analysis, the number indicates the relative
size of the estimated coefficient in the final model.
doi:10.1371/journal.pone.0011789.g001
ERBB3 and Type 1 Diabetes
PLoS ONE | www.plosone.org 3 July 2010 | Volume 5 | Issue 7 | e11789selection approach based on the Bayesian Information Criterion
(BIC) selected only two SNPs: one in between SUOX and IKZF4
(rs1701704) and rs1052165. Using lasso regression selected five
SNPs: rs1701704, rs1052165, a SNP within RAB5B (rs773107),
rs4759228, and a SNP within ERBB3 (rs2292238). The OR
estimates from the final models for the stepwise approaches were
at least 1.5. The OR estimates from the lasso analysis were smaller
due to the shrinkage used. Only two of the SNPs had an OR of at
least 1.2 based on this analysis (rs1701704 and rs1052165). These
results suggest that the association observed within this region may
be due to multiple genes. However, the precise number, location
and identity of the disease genes could not be determined using the
genetic association data.
SNP association with ERBB3 mRNA levels in PBMCs
Since the association data did not allow us to identify the most
likely candidate SNPs or genes, we searched for potential
association between genotype and gene expression to identify
candidate genes. The expression of six genes (RAB5B, SUOX,
IKZF4, RPS26, RPL41,a n dERBB3) located in the 12q13
association interval were analyzed in 384 subjects (192 T1D
patients and 192 controls with similar age and sex distribution).
The HLA genotypes were not matched between cases and
controls. All genes were detectable in PBMCs using real-time
RT-PCR. Regression modeling was used to examine the
relationship between SNP genotype and gene expression using
T1D status as a covariate. These analyses indicated that the
expression levels for four genes (RAB5B, IKZF4, RPS26 and
RPL41) did not depend on the genotypes in the 12q13 region
(Figure 2a). IKZF4 is an excellent candidate for T1D
susceptibility gene in the region because it is important for the
function of regulatory T cells [13]. While our data cannot
exclude IKZF4 as a candidate gene, the lack of expression-
genotype correlation decreased the priority for this gene in our
subsequent studies. Previous reports based on genome-wide
expression and SNP data [14–17] suggested that RPS26 may be
a good candidate gene. Our inability to confirm this finding
decreased the priority for subsequent studies. SUOX mRNA
levels showed marginally significant association with several
S N P sa n ds h o u l db ef u r t h e ri n v e stigated in future studies.
However, the most interesting finding from the gene expression
studies was on ERBB3 which showed a highly significant
(p,10
210) association between expression levels and genotypes
at multiple SNPs (Figure 2a).
A Student t-test also suggests that the mRNA levels of ERBB3
differ by more than two-fold between the homozygous genotypes
at rs2292239 (SNP #14) and rs4759228 (SNP #16) (Figure 2b).
These analyses indicate that ERBB3 mRNA levels are significantly
lower (p=1.1610
29 and 1.4610
26, respectively) for the minor
allele homozygotes (susceptible genotype) at rs2292239 and
rs4759228 (Figure 2b), suggesting that reduced ERBB3 expression
is associated with genotypes that confer increased risk for T1D.
Up-regulation of surface ERBB3 in CD11c
+ cells by
infection mimics
This study is the first to detect expression of ERBB3 in the
PMBC. However, the immune cell type(s) that express ERBB3
were not identified by the gene expression studies. To identify
the specific cell types of PBMC that express ERBB3, we
evaluated several monoclonal antibodies and identified one
clone that can be used for FACS analysis. Surface ERBB3 was
almost undetectable in fresh PBMCs (Figure 3a); however,
surface ERBB3 protein was dramatically increased after cultures
with three different infection mimics (LPS, polyI:C and CpG)
(Figure 3a). Co-staining of PBMC with the anti-ERBB3
antibody and cell-type-specific antibodies indicated that almost
all ERBB3
+ PBMCs express CD11c, a marker for monocytes
and dendritic cells (DC), and CD14, a monocyte marker; while
few T cells (CD3
+) and B cells (CD19
+)a r ep o s i t i v ef o rE R B B 3
on the cell surface (Figure 3b). These results suggest that
monocytes express surface ERBB3. To determine whether DC
also expresses ERBB3, we co-stained PBMCs with antibodies
against ERBB3, CD11c and CD14. As shown in Figure 3c, a
subset of DC (CD11c
+CD14
2 cells) also expresses ERBB3 after
treatment with the three infection mimics.
Genotype-dependent ERBB3 surface expression
During our studies of ERBB3 surface expression, we observed
individual variation in surface ERBB3 after in vitro treatment
with infection mimics. Therefore, we expanded our studies to 39
randomly selected control subjects. After culture of the PBMCs
with various conditions, the cells were stained with anti-ERBB3
and anti-CD11c antibodies. The results revealed high inter-
individual variability (Figure 4a, 4b & 4c). For example, 46%,
23% and 31% of the subjects have high (18–79%, mean=42%),
medium (8–16%, mean=12%) and low (,1.6%, mean=0.7%)
percentages of ERBB3
+ cells after 24 hour stimulation with
LPS. Furthermore, after LPS, CpG or polyI:C treatment, there
were high percentages of ERBB3
+ cells (Figure 4b). In contrast,
treatment with IFN-b or estrogen do not have a significant role
in inducing ERBB3 compared to medium (Figure 4c).
To further elucidate the mechanism underlying the individual
variation in surface ERBB3 expression, we examined the
association between the percentages of ERBB3
+ cells and a
number of variables including, sex, age and ERBB3 genotypes.
Consistent with the association between ERBB3 mRNA levels
Table 2. Association between T1D and haplotypes in the
12q13 region.
LD Blocks
Haplo-
types
Case
freq
Ctrl
freq P-value OR LCI UCI
Block 1a ATT 0.62 0.68 2610
27 0.8 0.7 0.8
SNP 4-5-6 GCC 0.37 0.31 7610
28 1.3 1.2 1.5
Block 1b CAT 0.60 0.67 2610
29 0.7 0.7 0.8
SNP 8-9-10 TCG 0.39 0.32 3610
29 1.4 1.2 1.5
Block 1a+1b ATTCAT 0.593 0.661 1.4610
28 0.7 0.7 0.8
GCCTCG 0.362 0.297 4.0610
28 1.3 1.2 1.5
ATTTCG 0.018 0.015 0.2862 1.2 0.8 1.8
Block 2 AGG 0.31 0.24 1610
29 1.4 1.3 1.6
SNP 14-15-16 CGG 0.01 0.01 0.4302 1.2 0.8 1.8
CTC 0.49 0.53 2610
24 0.8 0.8 0.9
ATC 0.04 0.06 0.0190 0.8 0.6 1.0
CTG 0.02 0.02 0.2246 0.8 0.6 1.2
AGC 0.03 0.04 0.8087 1.0 0.7 1.3
CGC 0.10 0.11 0.4843 0.9 0.8 1.1
Maximum-likelihood haplotype frequencies were estimated between cases and
controls using Haploview version 4.1. P-values below 0.05 were considered
significant and corrections were made by multiple testing (1000 permutations).
LD block 2 contains the ERBB3 gene and the strongest association is observed
with a haplotype in the block ‘‘AGG’’. The first 2 SNPs in this block are located at
the 39 end of ERBB3 and SNP #15 is 11kb downstream of the gene and 59 of the
RPL41 gene.
doi:10.1371/journal.pone.0011789.t002
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of ERBB3
+ cells after stimulation differed between ERBB3
genotypes at multiple SNPs including rs2292239 and rs4759228
(data not shown). We then used regression analysis to examine
whether two SNPs could improve the association between
genotypes and the percentages of ERBB3
+ cells. For these
analyses, we included a single SNP in LD sub-block 2, one at a
time, and then added the remaining SNPs, one at a time. The
results indicate that the additive effects of both rs2292239 and
rs4759228 contribute to differences in ERBB3 expression
(Figure 4d). Therefore, we calculated the mean percentages of
ERBB3
+ cells for three two-locus genotypes (AC/CC, AC/CG
and CC/CC). The CC/CC genotype, composed of the
protective CC homozygote at rs2292239 and the protective
CC homozygote at rs4759228, had the highest mean percent-
ages of ERBB3
+ cells. The differences between these two-locus
genotypes were quite large and consistent across all culture
conditions (Figure 4e). These results for the ERBB3 surface
protein, together with the data on ERBB3 mRNA, provide
strong evidence that ERBB3 gene and surface protein expression
is genotype-dependent.
The percentages of ERBB3
+ cells correlate with APC
function
Since ERBB3 is mainly expressed in CD11c
+ antigen presenting
cells, we hypothesized that ERBB3 may play an important role in
APC function. This hypothesis was first tested by evaluating the
ability of APC with different percentages of ERBB3
+ cells to
stimulate T cell proliferation. To avoid variation from responder T
cells, we purified responder CD4
+ T cells from one single healthy
donor. The responder CD4
+ T cells were stimulated by irradiated
PBMCs from different subjects who have different percentages of
ERBB3
+ cells after stimulation with LPS or polyI:C. The
proliferation of the responder T cells was highly variable and
ranged from 1,000 CPM to 100,000 CPM among the tested
PBMCs. Consistent with our hypothesis, regression analyses
suggested that the proliferation of responder T cells was
significantly associated with the percentages of ERBB3
+ cells of
Figure 2. Evidence for association between SNPs and ERBB3 gene expression in PBMCs. (a) Associations between each of the 19 SNPs and
the expression of each of the 12q13 genes were assessed by regression that included the additive effect of each SNP and T1D status. The 2Log10 p-
value for each comparison was plotted against the genomic order of the 19 SNPs. ERBB3 expression showed strong association with multiple SNPs
including one SNP in the middle (rs2292239) and one SNP at the 39 end (rs4759228) of the ERBB3 gene. (b) The mean expression of ERBB3 was
presented for the three genotypes at rs2292239 and rs4759228, respectively. The mean expression level was arbitrarily set to 1 for the minor allele
homozygous genotype at each SNP. P-values are for the additive effect of the SNP in a regression model.
doi:10.1371/journal.pone.0011789.g002
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with high percentages (.10%) of ERBB3
+ cells had an 8-fold
higher stimulation capacity than APC from subjects with low
percentages (,1%) of ERBB3
+ cells (p=1.6610
28, Figure 5c).
The stimulation capacity of APC is potentially influenced by many
factors including HLA and costimulatory molecules. The HLA
genotypes were not matched between subjects with low and high
percentages of ERBB3
+ cells. However, there was no significant
association between HLA and the stimulation capacity of the APC
(data not shown). This result is not surprising because our
stimulation condition contains anti-CD3 and anti-CD28 antibod-
ies which can minimize differences due to HLA. We also measured
the expression levels of three costimulatory molecules (CD86,
CD80 or CD40). There was no difference in CD40 expression
between APC with high and low stimulation activity (Figure 5d &
5e). CD80 expression was slightly but not significantly higher in
APC with high stimulation activity than APC with low stimulation
activity (Figure 5d & 5e). Interestingly, the mean CD86 level is
significantly higher in APC with high stimulation activity than
APC with low stimulation activity in both LPS stimulated cells
(Figure 5d, p=0.0009) and polyI:C stimulated cells (Figure 5e,
p=0.01). However, the correlation between CD86 levels and the
stimulation function of APC is very poor (R
2,0.2, Figure 5f).
Therefore, CD86 cannot explain the correlation between ERBB3
and APC’s stimulation function.
Discussion
This study provided strong evidence for association between
T1D and multiple SNPs and haplotypes in the 12q13 region in the
Georgia Caucasian population. Together with the results from the
published reports, there is now convincing evidence for this
association interval. Based on our genetic association data, thirteen
SNPs located within an expanded 150kb genomic region showed
strong evidence for association. Although associations across large
genomic regions could be explained by LD between SNPs, our
results suggested the possibility of multiple T1D genes in this
12q13 region. However, the genetic mapping data in this study or
in previous studies did not provide conclusive evidence that allows
the identification of specific SNPs or genes responsible for the
observed association. Several previous genome-wide studies on
SNP-gene expression association identified a significant association
between the RPS26 gene in the 12q13 region and SNPs within
ERBB3 and near RPS26 in B cell lines [16,17], liver [14], brain
and PBMC [14,15]. It has been suggested that RPS26 is a strong
candidate gene for the observed genetic association with T1D.
This study, with a large sample size, did not find any evidence for
association between RPS26 expression and SNP genotypes.
Furthermore, a previous report suggested that RPS26 expression
is unlikely to be the molecular phenotype responsible for T1D
susceptibility in this region [18]. Given the controversial
conclusions in different studies and the lack of functional data,
we believe that additional studies are required to determine
whether RPS26 is a T1D susceptibility gene.
In this study, our real-time RT-PCR analysis of gene expression
in PBMC identified two possible genes with significant genotype-
expression association. While SUOX showed a genotype-expres-
sion association and should be further studied for its potential role
in T1D, ERBB3 stood out as the most promising candidate gene
for T1D due to the observed highly significant genotype-
Figure 3. ERBB3 protein expression on the surface of PBMCs. (a) Representative FACS profiles for surface ERBB3. All panels are dual staining
for ERBB3 and CD11c. The left top panel (Fresh) is an example for staining of freshly isolated PBMCs. All other panels are staining for PBMCs that were
cultured for 24 hours with one of the five stimuli or medium alone. (b) Staining for ERBB3 in different lymphocyte subsets in PBMCs. With the
exception of ‘‘cell only’’, all panels were stained for ERBB3 and another antibody labeled underneath the panel. (c) Three-color staining of PBMCs for
ERBB3, CD11c and CD14. Shown is ERBB3 expression on dendritic cells (CD11c
+CD14
2).
doi:10.1371/journal.pone.0011789.g003
ERBB3 and Type 1 Diabetes
PLoS ONE | www.plosone.org 6 July 2010 | Volume 5 | Issue 7 | e11789expression association. Therefore, our subsequent efforts focused
on ERBB3. Although genotype-expression association and geno-
type-disease association together are important indications for
disease genes, such evidence alone is not definitive proof for
causality. In addition to the genetic and functional associations,
the candidate gene must be functionally relevant to the disease
pathogenesis. ERBB3 encodes a member of the epidermal growth
factor receptor (EGFR) family of receptor tyrosine kinases [19]. It
is a membrane-bound protein with a neuregulin binding domain
but without an active kinase domain [20]. It can bind its ligand
without conveying the signal into the cell through protein
phosphorylation. However, the heterodimers formed with other
EGF receptor family members that do have kinase activity lead to
the activation of pathways involved in cell proliferation or
differentiation. ERBB3 is widely known for its role in cancer as
amplification of this gene and/or over-expression of its protein
have been shown in numerous cancers, including prostate,
bladder, gastric cancer, and breast tumors [21–25]. ERBB3 is
suspected to be a good candidate gene for T1D because it is
known to be expressed in pancreatic beta cells and ductal cells
[26,27].
The current study suggests for the first time that ERBB3 plays a
critical role in immune regulation. We have demonstrated that
ERBB3 is expressed on the surface of CD11c
+ cells (monocytes
and DC) upon in vitro stimulation by infection mimics, suggesting
that ERBB3 may play an important role in innate immune
response. Consistent with this view, we have shown that the ability
of APC to stimulate T cell proliferation is highly significantly
correlated with the percentage of ERBB3
+ cells. However, how
ERBB3 modulates APC function requires further investigation. As
an EGF family receptor, ERBB3 and its heterodimeric partners
are known to influence the expression of a large number of genes
including growth factors, cytokines and transcriptional control
[28], which play critical roles in immune response and regulation.
ERBB3 is critical to the activation of the ERBB3-PI3K-Akt
cascade induced by EGFR/ERBB3 heterodimers [29]. Deficiency
or inhibition of the PI3K pathway can lead to reduced numbers of
regulatory T cells and autoimmunity [30].
Our data suggest that the percentage of ERBB3
+ cells is
correlated with the ability of APC to stimulate T cell proliferation.
In our study, we assessed the proliferation of the same CD4
+ T
cells responding to APC from individuals with different genetic
Figure 4. Surface ERBB3 expression depends on the types of stimulation and SNP genotypes. (a) Mean percentage of ERBB3
+ cells
among CD11c
+ PBMCs after culture with medium alone (Med) or different stimulation: Est (estrogen), IFN-b, IC (polyI:C), CpG and LPS. (b) Inter-
individual variation of percentage of ERBB3
+ cells among CD11c
+ PBMCs after stimulation. Data were Log 2 transformed. Data points for cultures with
medium alone (Med) and one stimulation (IC, CpG or LPS) in each individual were linked to illustrate the changes in ERBB3 under different culture
conditions. (c) The impact of IFN-b and estrogen on ERBB3 expression. The data are presented in similar ways as in (b). (d) The association between
percent of ERBB3
+ cells in CD11c
+ PBMCs and SNP pairs. Regression was used to examine whether two SNPs could improve the association between
% of ERBB3
+ cells and genotype. The 2Log10 p-value for each SNP added to a model that already included SNP rs4759228 was plotted against the
genomic order of the SNPs. These results indicate that the percentages of ERBB3
+ cells are partially determined by genotypes within/near the ERBB3
gene. (e) Mean percentages of ERBB3
+ cells were presented according to culture conditions and two-locus genotypes at rs2292239 and rs4759228.
doi:10.1371/journal.pone.0011789.g004
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different HLA genes in those individuals may also contribute to
the varying degree of proliferation of responder T cells. However,
the influence of HLA heterogeneity is minimized by adding anti-
CD3 and anti-CD28 antibodies, and HLA could not explain the
observed differences in APC function. LPS, CpG and others
stimuli are known to change the expression profiles of many other
genes in addition to ERBB3, which may affect the antigen
presenting function of APCs. Indeed, our data suggest that CD86
expression levels may be partly responsible for the differences in
APC function. However, CD86 cannot explain the correlation
observed between ERBB3 and APC function. It remains unknown
whether ERBB3 is directly implicated in the stimulation of T cell
proliferation. Based on the known function of ERBB3, it is more
likely that the expression of ERBB3 may influence the gene
expression profiles in APC and therefore indirectly modulate APC
function. APC can influence susceptibility to autoimmunity
through different mechanisms including deletion of autoreactive
T cells, activation of regulatory T cells and immune deviation.
Irrespective of the precise immunological mechanisms, our study
suggests that ERBB3 may be an important molecular link between
genetic susceptibility, infection and the adaptive immune response,
which are all believed to contribute to T1D pathogenesis.
Methods
Ethics statement
This study was approved by the Medical College of Georgia
Institutional review Board. All patients provided written informed
consent for participation in the study and donation of samples.
Patient population
The study population consists of Caucasian T1D patients and
healthy controls from Georgia and has been used in previous
studies [31]. The data set includes 1,434 patients and 1,865
controls. All diabetic patients were diagnosed using the criteria of
the American Diabetes Association. Most of the cases (893)
developed T1D at or before the age of 17 years (referred to as
early onset), while 541patients developed diabetes after 17 years of
age (referred to as late onset). The normal controls do not have a
family history for T1D and were ascertained from the same
geographic area as the patients.
Genotyping
The SNPs were genotyped using TaqMan-assays designed and
validated by Applied Biosystems [32]. Amplification reactions
Figure 5. Impact of ERBB3 on APC function. (a) Correlation between APC function (ability to stimulate T cell proliferation) and percentages of
ERBB3
+ cells of the APC source. Each dot represents one individual plotted based on their percentage of ERBB3
+ cells after LPS stimulation and the
associated proliferation. (b) Correlation between APC function and ERBB3 after polyI:C stimulation. (c) Association between T cell proliferation and
percentage of ERBB3
+ cells of the APC source. PBMCs were cultured for 24 hours with LPS or polyI:C and then irradiated and used as APC to stimulate
the proliferation of responder T cells purified from one healthy donor. The mean proliferation (CPM) was calculated for subjects with high ERBB3 (H)
defined as having .10% ERBB3
+ cells among CD11c
+ PBMCs and low ERBB3 (L) defined as having ,1% ERBB3
+ cells. Student t-test was used to
assess statistical significance. (d) FACS analysis of CD86, CD80 and CD40 on PBMCs after in vitro culture. The means and standard deviations (mean
fluorescent intensity=MFI) for subjects with low or high proliferation were presented for CD86, CD80 and CD40. Cells were stimulated with LPS. (e)
Expression levels of CD86, CD80 and CD40 after polyI:C stimulation. Results were presented as described in (d). (f) Correlation between CD86
expression (MFI on the Y axis) and responder T cell proliferation (CPM on the X axis).
doi:10.1371/journal.pone.0011789.g005
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PCR was carried out with 2 min at 50uC, 10 min at 95uC
followed by 40 cycles of 15 sec at 95uC and 1 min at 60uCu s i n g
an ABI 7900HT Fast Real-Time PCR system (Applied
Biosystems).
Gene expression assays by real-time RT-PCR
Peripheral blood was immediately preserved in the PaxGene
RNA tubes. After two hours at room temperature, the tubes were
frozen at 280uC freezers and total RNA was extracted within a
few weeks using a Qiagen kit specially developed for the PaxGene
RNA tubes. Extracted RNA was stored at 280uC freezers till use.
An aliquot of 2ug RNA were arrayed in 96-well plates and then
converted to cDNA using a High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). The cDNA products are
diluted and an aliquot of cDNA equivalent of 10ng total RNA
was used for quantitative real-time PCR performed using
TaqMan assays from the Applied Biosystems. Assays include
ERBB3 (Hs00176538_m1), RAB5B (Hs00161184_m1), SUOX
(Hs00166578_m1), RPL41 (Hs00606029_g1), RPS26
(Hs00762561_s1) and IKZF4 (Hs00223842_m1). The 18s rRNA
(Hs 99999901_s1) and GAPDH (Hs99999905_m1) were used as
endogenous control for normalizing RNA concentration. Real-
time PCR was performed in 384-well plates with the ABI
7900HT Fast Real-Time PCR System. Standard thermal cycling
condition (10 min at 95uC, 40 cycles for 15 sec at 95uC, 1 min at
60uC) was used for all genes. A total of 384 samples (192 T1D
and 192 controls) were analyzed. Cycle threshold (CT)v a l u e sf o r
each gene were obtained for each sample using the SDS2.3 and
analyzed with RQ Manager 1.2 software. Differences in CT
values between a test gene and endogenous controls (18s rRNA
and GAPDH) (DCT) were calculated and used for statistical
analyses.
Cell culture
PBMCs were isolated by Ficoll-paque density gradient
centrifugation. Cells were cultured in RPMI 1640 medium
(Cellgro, VA) with 10% FBS (Sigma, MO), 5 mM HEPES (Fisher
Scientific, NJ), penicillin (50 mg/ml), streptomycin (50 mg/ml),
1mM sodium pyruvate (Cellgro, VA)) and 50 mM 2-mercapto-
ethanol (Invitrogen, NY) in 24 and 96-well plates (Costa,
Cambridge, MA). For stimulation, 1610
6 cells were cultured in
24-well plate and then treated with 1 mg/ml LPS (Sigma, MO),
0.5 mM CpG (ODN2006, AXXORA, CA), 1 mg/ml estrogen
(Sigma, MO), 300IU/ml IFN-b (Sigma, MO) and 12.5 mg/ml
poly(I:C) (Sigma, MO) for 24h.
FACS analysis
For each staining, 5610
5 PBMCs were resuspended in 100ml
PBS buffer, blocked with human FcR blocking reagent (Miltenyi)
for 10 min, then stained with antibodies: APC-anti-CD11c (clone:
B-ly6, BD PharMingen), PE anti-ERBB3 (clone:66223, R&D
Systems), APC-anti-CD19 (BD PharMingen), FITC-anti-CD14
(BD PharMingen) and FITC-Lin 1 (CD3, CD14, CD16, CD19,
CD20 and CD56) (BD Biosciences) and then incubated on ice in
the dark for 40 min. 7-AAD was used for gating out dead cells. For
cell subset analysis, 2.5610
6 cells were used. Background
fluorescence was assessed using appropriate isotype antibodies.
Fluorescence was quantified using a FACS Calibur flow cytometer
(BD Biosciences). Cells were electronically gated on forward angle
light scatter to exclude contaminating erythrocytes and small
debris and on 90u light scatter to exclude granulocytes. Data were
analyzed using Cell Quest.
T cell stimulation assay
Peripheral blood (,20 ml) was collected in sodium-heparin
vacutainer tubes from one single healthy donor. CD4
+ T cell
population was isolated using a human CD4
+ T cells enrichment
cocktail (Stem Cell). CD4
+ T cells (5610
4 or 2.5610
4 cells per
well) were co-cultured with irradiated PBMC (1610
5 or 0.5610
5
cells per well) after culture with LPS or polyI:C. A stimulus of 0.5
or 0.25 mg/ml soluble anti-CD3 (clone HIT3a) and 0.25 or
0.125 mg/ml soluble anti-CD28 (clone CD28.2; BD Pharmingen)
were added in the co-culture medium. After 48h, 0.5 mCi
3H-
thymidine (Amersham Biosciences, Piscataway, NJ) was added for
the final 16h of culture to assess CD4
+ T cell proliferation.
Statistical analysis for SNP association
Association between each SNP and T1D status was assessed
using different methods. Since the results were very similar, we
only presented the data from logistic regression with an additive
model. We examined the potential effects of sex and HLA risk by
including these variables as covariates in the additive genetic
model of a logistic regression. We used the Breslow-Day test to
examine heterogeneity in the ORs between low- and high-risk
HLA-DQB1 subsets. The early and late onset patients were
analyzed separately and jointly to examine the potential influence
of age of onset on the SNP associations. Given the strong signal
observed throughout the region and the strong linkage disequilib-
rium in this region, we used logistic regression as the basis for
determining which SNPs showed independent effects. Two
stepwise approaches and one model selection/shrinkage approach
were used for this purpose [33]. In all models, we used additive
SNP effects with no interactions. In the first approach, we
sequentially added SNPs to the model based on the largest chi-
squared test for the added SNP, until no additional SNP was
significant. In this approach, we used all of the samples to increase
power. Sample sizes decreased as SNPs were added due to subjects
having incomplete genotype information for all SNPs. For the
other two approaches, we only used the data for subjects having
complete genotype data for all SNPs. In the second approach, we
used the Bayes Information Criterion (BIC) to add SNPs. The
single SNP model with the smallest BIC was chosen in the first
step, with subsequent SNPs being added based on the model
having the smallest BIC, provided the BIC was smaller than the
accepted model from the previous step. The third approach that
we used was lasso-based shrinkage.
Statistical analysis for gene expression and FACS data
Gene expression differences between SNP genotypes were
examined by student t-test in some analyses and by a regression
model in which the association between gene expression and SNP
genotype was additive, which is equivalent to asking whether a
trend exists in the association between gene expression and SNP
genotype. In such models, the estimated mean for the heterozygote
will be equal to the average of the homozygotes. Analyses to
examine the potential role of multiple SNPs utilized models that
included two SNPs, each with an additive effect. These models
also included the effect of T1D status and all interaction. All
mixed-model analyses were conducted using the Proc Mixed
procedure of SAS, and models without random effects were
conducted using the Proc GLM procedure.
FACS data were analyzed using student t-tests and regression
modeling. The differences between genotypes were examined
using an additive model, similar to the analyses conducted for the
expression data. We initially included the additive effects of two
SNPs in one model to examine the potential role of multiple loci.
Since not all two-locus genotypes were observed in our study, we
ERBB3 and Type 1 Diabetes
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subjects. For this case, we used the effect of two-locus genotype in
a one-way ANOVA.
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